Drug intelligence / Profile preview

etheno-NAD

Development stage: Unknown
Modality: Small Molecules

Overview

Etheno-NAD (1,N6-ethenoadenine dinucleotide, ε-NAD) is a fluorescent analog of nicotinamide adenine dinucleotide (NAD). It is primarily used as a research tool rather than as a therapeutic drug. Etheno-NAD is intensely fluorescent and serves as a substrate for various NAD-dependent enzymes in biochemical assays. Its fluorescence properties allow sensitive detection and quantification of enzyme activities such as ADP-ribosylation and poly(ADP-ribose) polymerase (PARP) activity in vitro. Etheno-modified nucleotides like etheno-NAD are not approved for clinical use but are valuable in experimental settings to study NAD metabolism, enzyme kinetics, and cellular processes involving NAD-utilizing enzymes[1][3][7].

Other names: etheno-NAD1,N6-ethenoadenine dinucleotideε-NAD

Targets

PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on etheno-NAD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on etheno-NAD.

Explore the full profile